Table 3. PFS, PFS2 and OS in primary and recurrent methylated vs. unmethylated ovarian cancer OS (overall survival), PFS (progression-free survival), PFS2 (progression free survival 2, time to next treatment) primary (primary tumor group), recurrent (recurrent tumor group), methylated (BRACA1 promoter methylation), unmehtylated (no BRACA1 promoter methylation), pts.: patients.
| Primary | Methylated | Unmethylated | |
|---|---|---|---|
| PFS (months), pts. | 16.8, n=56 | 15.3, n=21 | p=0.29, HR: 0.85, (95%CI: 0.51-1.4) |
| PFS2 (months), pts. | 36.2, n=45 | 40, n=16 | p=0.43, HR: 0.93 (95%CI: 0.52-1.6) |
| OS (months), pts. | 46.75, n=56 | 50.6, n=21 | p=0.24, HR:0.79, (95%CI: 0.44-1.42) |
| Recurrent | Methylated | Unmethylated | |
|---|---|---|---|
| PFS, pts. (months) | 23.1, n=10 | 23.4, n=38 | p=0.46, HR: 0.95, (95%CI: 0.48-1.97) |
| PFS2, pts. (months) | 51.3, n=8 | 53.1, n=18 | p=0.22, HR: 1.51, (95%CI: 0.52-1.6) |
| OS, pts. (months) | 71.3, n=10 | 89.6, n=38 | p=0.22, HR: 1.7, (95%CI: 0.63-4.48) |